Bupivacaine HCl (Synonyms: AH 2250, (±)-1-butyl-2′,6′-Pipecoloxylidide) |
| رقم الكتالوجGC12410 |
Bupivacaine HCl هو أحد مثبطات مستقبلات NMDA.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 18010-40-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
| Cell experiment [1]: | |
|
Cell lines |
FDB muscle fibers |
|
Preparation method |
The solubility of this compound in DMSO is > 10.3 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
1 mM; 40 mins |
|
Applications |
In FDB muscle fibers treated with 1 mM Bupivacaine HCl for 40 mins, the TMRM signal was substantially lost and the fiber shortened significantly. The TMRM signal decreased within about 30 mins, and depolarization was inhibited by CsA, which indicated that Bupivacaine facilitated the opening of the permeability transition pore, eventually causing mitochondrial depolarization. |
| Animal experiment [2]: | |
|
Animal models |
ACLT osteoarthritic rats |
|
Dosage form |
0.5%, 10 mL; intra-articular injection; once a week for 5 consecutive weeks |
|
Applications |
In ACLT osteoarthritic rats treated with Bupivacaine HCl, the relative weight-bearing values were significantly lower at the 6th and 7th weeks. Besides, Bupivacaine HCl did not show any significant effect on the viability and density of chondrocytes, as well as the histological characteristics of articular cartilage when compared with saline solution injections. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Irwin W, Fontaine E, Agnolucci L, Penzo D, Betto R, Bortolotto S, Reggiani C, Salviati G, Bernardi P. Bupivacaine myotoxicity is mediated by mitochondria. J Biol Chem. 2002 Apr 5;277(14):12221-7. [2]. Iwasaki K, Sudo H, Kasahara Y, Yamada K, Ohnishi T, Tsujimoto T, Iwasaki N. Effects of Multiple Intra-articular Injections of 0.5% Bupivacaine on Normal and Osteoarthritic Joints in Rats. Arthroscopy. 2016 Oct;32(10):2026-2036. |
|
| Cas No. | 18010-40-7 | SDF | |
| المرادفات | AH 2250, (±)-1-butyl-2′,6′-Pipecoloxylidide | ||
| Chemical Name | 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide;hydrochloride | ||
| Canonical SMILES | CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C.Cl | ||
| Formula | C18H28N2O.HCl | M.Wt | 324.89 |
| الذوبان | ≥ 10.25mg/mL in DMSO | Storage | 4°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.078 mL | 15.3898 mL | 30.7796 mL |
| 5 mM | 0.6156 mL | 3.078 mL | 6.1559 mL |
| 10 mM | 0.3078 mL | 1.539 mL | 3.078 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *